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Objective
This report documents that the gastric bypass operation provides long-term control for obesity
and diabetes.
Summary Background Data
Obesity and diabetes, both notoriously resistant to medical therapy, continue to be two of our
most common and serious diseases.
Methods
Over the last 14 years, 608 morbidly obese patients underwent gastric bypass, an operation that
restricts caloric intake by (1) reducing the functional stomach to approximately 30 mL, (2) delaying
gastric emptying with a c. 0.8 to 1.0 cm gastric outlet, and (3) excluding foregut with a 40 to 60
cm Roux-en-Y gastrojejunostomy. Even though many of the patients were seriously ill, the
operation was performed with a perioperative mortality and complication rate of 1.5% and 8.5%,
respectively. Seventeen of the 608 patients (<3%) were lost to follow-up.
Results
Gastric bypass provides durable weight control. Weights fell from a preoperative mean of 304.4 lb
(range, 198 to 615 lb) to 192.2 lb (range, 104 to 466) by 1 year and were maintained at 205.4 lb
(range, 107 to 512 lb) at 5 years, 206.5 lb (130 to 388 lb) at 10 years, and 204.7 lb (158 to 270 lb)
at 14 years.
The operation provides long-term control of non-insulin-dependent diabetes mellitus (NIDDM).
In those patients with adequate follow-up, 121 of 146 patients (82.9%) with NIDDM and 150 of 152
patients (98.7%) with glucose impairment maintained normal levels of plasma glucose,
glycosylated hemoglobin, and insulin. These antidiabetic effects appear to be due primarily to a
reduction in caloric intake, suggesting that insulin resistance is a secondary protective effect
rather than the initial lesion. In addition to the control of weight and NIDDM, gastric bypass also
corrected or alleviated a number of other comorbidities of obesity, including hypertension, sleep
apnea, cardiopulmonary failure, arthritis, and infertility.
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Conclusions
Gastric bypass is now established as an effective and safe therapy for morbid obesity and its
associated morbidities. No other therapy has produced such durable and complete control of
diabetes mellitus.
Non-insulin-dependent diabetes mellitus (NIDDM),
the form of diabetes that afflicts more than 90% of the
14 million diabetic Americans, is notoriously resistant to
treatment. The current therapies, including insulin, diet,
exercise, behavior modification, and oral agents, rarely
return patients to long-term euglycemia. Further, these
therapies have not been shown to reduce the incidence
of the complications of diabetes, including stroke, myo-
cardial infarction, loss of vision, renal failure, ampu-
tations, and neuropathies.
This report details our experience with the gastric by-
pass operation in a series of 330 of608 (54.3%) morbidly
obese patients who had either NIDDM or impaired glu-
cose tolerance (IGT). Operative management restored
and maintained normal levels of glucose, insulin, and
glycosylated hemoglobin in 91% of the patients for as
long as 14 years. This degree of diabetic control is far
better than any reported by medical means.
METHODS
Since 1980, 608 morbidly obese patients were treated
with the Greenville modification of Mason's gastric by-
pass operation. The operations were performed on 404
white (66.4%) and 102 African American (16.8%)
women and on 87 white (14.3%) and 15 African Ameri-
can (2.5%) men. The average age at the time of surgery
was 37.3 years (range, 14 to 64 years). Preoperative
weights of the group ranged from 198 to 615 lb, with a
mean of 304.4 lb. Of these 608 individuals, 364 (59.9%)
were employed: two as executives or major professionals;
52 as managers, professionals, or owners of medium
businesses; 46 as administrators, semiprofessionals, or
small business owners; 122 as technicians or clerical/
sales workers; 79 as skilled workers; 42 as semiskilled
workers; and 21 as laborers. Two hundred forty-four
(40.1%) were not employed. Marital status inquiries re-
vealed that 418 (68.8%) were married, 54 (8.9%) were
divorced, 25 (4.1%) were separated, 11 were (1.8%) wid-
owed, and 100 (16.4%) had never married.
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Of these 608 morbidly obese patients, 165 (27%) had
NIDDM, and another 165 (27%) had IGT. Before sur-
gery, 353 (58.1%) ofthe patients had hypertension.
Ofthe initial 608 patients who underwent surgery, 553
of the 574 living patients maintained contact over the
14 years, a follow-up rate of 96.3%. After surgery, 599
(98.5%) survived the perioperative period and 574
(94.4%) are currently alive. Of these, 281 (49%) were ex-
amined in the clinic and 272 (47%) were interviewed by
phone over the last year. Information was received from
the family for 4 (1%) patients, and 17 patients (3%) were
lost to follow-up.
Patient Selection
Patients between the ages of 14 and 65 years were ac-
cepted for evaluation for bariatric surgery if they had a
body mass index (BMI, kg/mi2) of .35 if comorbidities
such as diabetes, cardiopulmonary failure, or arthritis ex-
isted or .40 if no comorbidities existed. Table 1 shows
ideal body weights and BMIs at each height as well as the
weights for these heights when BMI values are 24 (con-
sidered normal weight by some), 35, and 40. Contraindi-
cations to surgery included a history of unresolved alco-
hol or substance abuse in the previous 5 years, depres-
sion, an inability or unwillingness to cooperate in long-
term follow-up, a lack ofunderstanding ofthe operation
and its consequences, an unrealistic expectation of out-
come, and failure to correct the medical conditions to a
degree to permit safe surgery. Strong immutable opposi-
tion from the family was a relative contraindication.
Preoperative Evaluation and Preparation
The evaluation of these patients as candidates for ba-
riatric surgery was simplified as we gained experience.
Even so, we continue to prefer a slow evaluation, that is,
over 2 to 3 months, to be certain that the patient and
the family are well educated about the operation and its
consequences. The first visit is used for the initial evalu-
ation, for the first screening to determine whether the pa-
tient is a candidate for bariatric surgery, for the distribu-
tion of educational materials, and, if the patient is
deemed suitable, for ordering of a psychologic evalua-
tion as well as a chest roentgenogram, upper gastrointes-
tinal series, complete blood count, SMA-17, thyroid-
stimulating hormone levels, urinalysis, electrocardio-
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Table 1. IDEAL BODY WEIGHTS FOR MEN AND WOMEN WITH COMPARISONS TO
WEIGHTS WITH BMIS AT 24, 35, AND 40*
Height (ft./in.) Height (cm) Weight (lb) Weight (kg) BMI BMI = 24 (lb) BMI = 35 (lb) BMI = 40 (lb)
Women
4'10"
4'11"
5'0"
5'1"
5,3,,5'3"
5,4,,
5,5,'
5'6"5,7,'517ff
5'8"
5'9"
5'10"
5'11 '
6'0"
Men
5'2
5,3,,
5'4"
5'5"
5'6ff
5'7"
,4,,
5'9"
5'10'
6'0"
6'2"
6'3"
6'4"
147
150
152
155
158
160
163
165
168
170
173
175
178
180
183
158
160
163
165
168
170
172
175
178
180
183
185
188
191
193
115
117
120
122
125
128
131
134
137
140
143
146
149
152
155
136
138
140
143
145
149
151
154
157
160
164
167
171
175
179
52.2
53.1
54.2
55.3
56.7
58.1
59.4
60.8
62.1
63.5
64.9
66.2
67.6
68.9
70.3
61.7
62.6
63.5
64.6
65.8
67.6
68.5
69.8
71.2
72.6
74.2
75.7
77.6
79.2
81.2
24
24
23
23
23
23
22
22
22
22
22
22
21
21
21
25
24
24
24
23
23
23
23
22
22
22
22
22
22
22
114
119
122
127
132
135
140
144
149
153
158
162
167
171
177
132
135
140
144
149
153
156
162
167
171
177
181
187
193
197
166
173
178
185
192
197
205
210
217
223
230
236
244
249
258
190
198
203
211
220
225
234
240
248
254
263
270
279
285
295
192
197
205
210
217
223
228
236
244
249
258
264
272
281
287
220
225
234
240
248
254
260
270
279
285
295
301
311
321
328
BMI = body mass index.
* Based on the 1983 tables from the Metropolitan Life Insurance Company, New York, New York. Surgery is the therapy of choice for weight control when the BMI .35 in a
patient with comorbidities such as diabetes and hypertension or when the BMI .40 in a patient without such comorbidities.
gram, and pregnancy test in women younger than age 50.
Every patient is seen by the project psychologist, because
depression and other emotional disorders are common
in the morbidly obese population. The decision to pro-
ceed with bariatric surgery is made on the second visit,
usually a month later, after the review of the various
study outcomes and another counseling session with the
patient. If the patient then requests the operation, addi-
tional consultations to evaluate and stabilize cardiac fail-
ure, pickwickian syndrome, sleep apnea, anemia, or pul-
monary function are requested if needed. Morbidly
obese patients who select surgical therapy have often ex-
hausted all other treatment options. They must be re-
garded as chronically ill individuals with complex medi-
cal problems, often burdened with 50 to 100 lb of excess
water, chronic malnutrition, and complex social con-
flicts. Insurance approval, occasionally difficult to ob-
tain, is also requested at this visit. The third visit occurs
within a week before surgery, at which time the opera-
tion, risks, alternatives, and benefits are again reviewed
and the preadmission hospital workup is completed.
Preoperative Preparation
Serious health problems need to be stabilized before
surgery. Skin lesions need to clear as much as possible,
and chronic problems, such as asthma, chronic pulmo-
nary infections, diabetes, and hypertension need to be
stabilized; if the patient is receiving medications, these
need to be reviewed and adjusted to appropriate levels.
Patients are generally admitted on the morning of sur-
gery. Complicated cases, however, such as those involv-
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Figure 1. The Greenville modification of the gastric bypass. The stomach
is partitioned to form a 20 to 30 mL proximal pouch that is connected to a
40 to 60 cm Roux-en-Y loop with an 8 to 10 mm double-layered gastroen-
terostomy. The biliopancreatic limb also measures 40 to 60 cm, depend-
ing on the mobility of the gut.
ing patients with cardiorespiratory failure, may require
several days of preparation in the hospital to bring them
to an optimal preoperative status. A cephalosporin is
given intravenously for prophylaxis the morning of sur-
gery and for 2 days thereafter.
Special equipment must be available for the care of
the morbidly obese. The clinics require seats, couches,
examining tables, and wheelchairs designed for individ-
uals who may weigh over 600 lb. In addition, sturdy
beds, strong gurneys, and X-ray that can accommodate
these patients are required in the hospital.
Description of the Operation
A diagram of the operation is shown in Figure 1. The
abdomen is entered through a high midline incision, and
exposure is provided by a mechanical retractor, such as
the Omni models (Omni-trak, St. Paul, MN). If the ex-
ploration demonstrates no contraindications, the upper
stomach is isolated by inserting the index finger gently
into the angle at the cardia to the left of the esophagus.
At this point, there is a weak, thin area of the posterior
peritoneum that is easily entered by the dissecting finger.
The dissection is gently continued behind the esophagus
and cardia and the finger brought out, not at the right
side of the esophagus but between the ascending
branches of the left gastric artery, 2.5 to 3.0 cm below
the esophagogastric junction. A No. 36 Malecot catheter,
from which the bulbous end has been cut, is used to pull
a TA90 stapling instrument through the passage. A prox-
imal pouch measuring 4 cm in width and 1.5 cm in
height, approximately the size of a thumb, is then pre-
pared by firing the staples. Two additional layers of sim-
ilar TA90 staples are then superimposed and fired over
the first set. A figure-of-eight suture is placed at each end
of the staple line to close the ends securely and to serve
as guy sutures. To prepare the Roux-en-Y, the jejunum
is divided 40 to 60 cm from the ligament of Treitz with
the GIA stapling instrument (Ethicon, Somerville, NJ)
and then threaded through the mesocolon and the lesser
sac and taken back out by the bare area of the greater
curvature. The proximal end of the distal jejunum is
then sutured to the gastric pouch. The anastomosis is
sewn to fit loosely around a 0.8-cm Salem SUMP tube
(Sherwood Medical Co., St. Louis, MO) in two layers
with continuous polypropylene. The Roux-en-Y enter-
oenterostomy is then completed by joining the proximal
jejunum end-to-side to the distal jejunum 60 cm below
the gastroenterostomy with GIA and TA55 stapling de-
vices. It is important to ensure that the intestine is not
constricted in its passage through the lesser sac, that the
Roux loop is attached to the mesocolon with three su-
tures to prevent an internal hernia, and that the enter-
oenterostomy is not bleeding from the internal staple
line before applying the TA55. The abdomen is closed
with a running double-stranded 0 PDS absorbable suture
(Ethicon, Somerville, NJ). The skin is stapled. The oper-
ation can usually be performed in 60 to 75 minutes;
blood loss rarely exceeds 300 mL. The first 519 gastric
partitions were done with a four-row TA90 stapling de-
vice. Since then, to avoid further staple line failures, we
have either divided the stomach or used the triple super-
imposed layers of double-row TA90 staples. Except for
the different approaches for partition, the operations
were identical and can therefore be evaluated as one co-
hort.
Postoperative Care
The postoperative care of bariatric patients demands
close attention. The first 24 hours are particularly critical
because ofthe great seriousness ofa leak or intra-abdom-
inal infection in these individuals. If the pulse remains
over 120, ifthere is a rise in temperature over 39 C., or if
the patient looks ill despite normal vital signs, emergency
exploration and additional types of antibiotics may be
needed. In such cases, swallow of a small amount of a
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water-soluble radiopaque agent followed by barium may
be helpful to detect an anastomotic leak. (Such tests are
not always reliable; we have several patients with leaks
who, on the first examination, demonstrated normal
passage of barium without extravasation.) Neglect of a
perforation or intra-abdominal infection is associated
with a high mortality rate. If there is doubt, it is best to
proceed with surgery; an unnecessary exploration is a lot
safer than a missed perforation.
Patients usually spend the first night on an intermedi-
ate unit with nurses who are familiar with bariatric care.
Patients are kept on nothing-by-mouth status until they
pass flatus, usually on the 3rd day, begun on half-
strength Ensure Plus (30 mL four times daily) with water
(30 mL every hour) on the 4th day, and full-strength En-
sure Plus with water, in the same doses, on the 5th or
6th day, when they are sent home. After discharge, the
patients are maintained on full fluids for 2 weeks and
then cautiously progress to a full diet by the end of 6
weeks. Most patients gradually return to their previous
diet in terms of variety but with a marked reduction in
quantity, because they fill up quickly and because the
gastric pouch empties slowly. Most patients cannot tol-
erate simple carbohydrates, such as candy, because ofthe
dumping induced by the gastroenterostomy. Meats may
present difficulties: we start slowly with fish, then pro-
gress to chicken, and finally, after some months, intro-
duce red meat. By the end of 3 months, most patients eat
a limited but well-balanced diet. Considerable counsel-
ing may be needed during the initial adjustment to the
operation so that the patients understand that the emesis
after overeating and the dumping after the ingestion of
candy are desirable side effects of the operation and that
these symptoms can be avoided by adherence to the di-
etary limitations.
The most common early complications seen in the
clinic are wound abscesses, and these, as might be ex-
pected, occur most commonly in the diabetic patients.
The wound infections generally present as red bulges that
drain spontaneously or that can be drained through a
small 1- to 2-cm opening of the incision. It is not neces-
sary to open the whole wound or significant lengths of
the incision; such interventions may lead to long-term
wound care and delays in healing. Late subphrenic ab-
scesses can usually be drained percutaneously with inter-
ventional radiologic techniques.
Long-Term Follow-up
Patients generally do remarkably well and are
delighted with their new body image, their freedom from
diabetes, and their new life. Daily long-term intake of
liquid or chewable total mineral and vitamin product is
Figure 2. Revision of a failed gastric bypass. The pouch is restored to
the original 20- to 30-cm size by dividing the stomach and resecting the
previous staple line en bloc with the gastroenterostomy. A new anastomo-
sis is then constructed to restore the 8- 10-mm gastric outlet. The forma-
tion of a fistula between the two gastric segments can be minimized by
oversewing the two staple lines and interposing a tongue of omentum.
essential; 600 ,ug/day of B12 is the recommended mini-
mum dose.' Omission ofthis may lead to severe anemia,
Wernicke-Korsakoff syndrome, or other neuropathies.
Weight gain exceeding 12% above the lowest postopera-
tive weight is generally the result of staple line break-
down, pouch or anastomotic dilatation, or compulsive
snacking. Abdominal pain is most commonly due to
cholecystitis, although some patients may develop mar-
ginal ulcers that clear quickly with histamine blockers
and, when indicated, with therapy for Helicobacter py-
lori. Recurrent vomiting usually signals overeating but
may be due to stenosis of the gastrojejunostomy. Such
strictures can almost always be relieved with one or two
dilatations of the anastomosis. Finally, these patients re-
quire considerable emotional support from their refer-
ring physician, the surgical staff, and their families. We
have found monthly support groups useful.
Revision of Failed Bariatric Procedures
All bariatric procedures have a failure rate, ranging
from 80% or more for horizontal gastroplasties to about
5% to 10% for the vertical banded gastroplasties and gas-
tric bypasses. Most of the failures are due to failed staple
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Table 2. WEIGHT LOSS IN 608 MORBIDLY
OBESE PATIENTS AFTER THE GASTRIC
BYPASS OVER 14 YEARS WITH 97%
FOLLOW-UP
Mean Weights % Excess Weight Body Mass
(lb) (range) Loss (range) Index
Preoperation 304.4 (198-615) 0.0 49.7 (33.9-101.6)
1 yr 192.2 (104-466) 68.9 (10.3-124) 31.5 (19.1-69.3)
5 yr 205.4 (107-512) 57.7 (-14.6-115.9) 33.7 (19.6-7.16)
10 yr 206.2 (130-388) 54.7 (-0.9-103.1) 34.7 (22.5-64.7)
14 yr 204.7 (158-270) 49.2 (7.2-80.9) 34.9 (25.9-54.6)
lines, stenosis of the gastric outlets, distended gastric
pouches, or dilated gastrojejunostomies. Revision of
these failures is technically challenging and associated
with a high complication and second failure rate. Our
most useful approach has been to (1) define the stomach
and the alimentary limb, (2) expose the pouch and pre-
vious anastomosis, (3) resect the old staple line and the
gastroenterostomy, and (4) reanastomose the jejunal
limb to the now-divided gastric pouch (Fig. 2).
RESULTS
Control of Disease
The operation produced significant and durable
weight loss. Table 2 demonstrates that the mean preop-
erative weight of 304.4 lb (range, 198 to 615 lb) drops to
192.2 lb (range, 104 to 466 lb) by the 1st year, a decrease
of 112 lb. Usually there is some additional loss by 18
months, followed by a remarkable stability of weight for
almost a decade and a half: 205.4 lb (range, 107 to 512
lb) at 5 years, 206.2 lb (range, 130 to 388 lb) at 10 years,
and 204.7 lb (range, 158 to 270 lb) at 14 years. Not only
has the mean weight ofthese patients at 14 years dropped
100 lb below their operative weights, but also, the maxi-
mum weights have diminished even more significantly,
from 615 lb to 270 lb. An average maximum weight loss
of 70% of excess body weight occurred approximately 2
years after surgery. At the end of 5 years, mean weight
loss was 58% of excess body weight; after 10 years, 55%;
and after 14 years, 49%. Similarly, the mean BMI levels
fell from 49.7 to 31.5, 33.7, 34.7, and 34.9 at 1, 5, 10,
and 14 years, respectively. The durability of the weight
loss is graphically illustrated in Figure 3.
Gastric bypass effectively reduced the proportion of
body fat. Measurements of body composition with hy-
drodensitometry (underwater immersion weighing) in
220 randomly selected patients demonstrated that the
percentage of fat in females fell from a preoperative
mean of 50.92% to 38.46% and in males from 46.70% to
31.93%.
Even more striking is the control of adult-onset diabe-
tes. Before surgery, 165 of 608 patients (27%) had
NIDDM and another 165 patients (27%) had IGT, how-
ever, a full set of data was not available for 19 ofthe 608
patients for technical reasons. Adequate follow-up data
are available on 298 glucose-intolerant patients follow-
ing surgery, 146 of 165 (88.5%) with NIDDM and 152 of
165 (92.1%) with IGT. Ofthese 298 patients, 271 (9 1%)
have maintained normal values of fasting blood glucose
and glycosylated hemoglobin, whereas 27 (9%) continue
to be diabetic. Among these 27 diabetic patients, 25 orig-
inally presented with NIDDM and 2 with IGT. As of
September 12, 1994, the date of the last annual sum-
mary, 121 of 146 patients (82.9%) who presented with
NIDDM maintained normal values ofblood glucose and
glycosylated hemoglobin.
The 165 patients with IGT were followed until death
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Figure 4. The correction of the hyperglycemia occurs rapidly. Patient 1
had an fasting blood glucose level of 495 mg/dL on the day before surgery
despite the administration of 90 U of insulin. By the end of the 1 st postop-
erative day, her fasting blood glucose level fell to 281 mg/dL and her
insulin requirement dropped to 8 U. By the 6th postoperative day, she no
longer required insulin.
or until September 12, 1994, for an average of 7.6 years
after gastric bypass surgery, for a total of 1254 patient
years of follow-up. Two patients (1.2%) who presented
with IGT progressed to NIDDM; of the others available
for study, 150 of 152 (98.7%) reverted to euglycemia.
(Compared with a similar IGT population who did not
undergo surgery, between 43 and 75 would have been
expected to progress to NIDDM2 within the same time
frame [95% confidence interval].)
The normalization of glucose metabolism occurred
with surprising speed, even before there was significant
weight loss. Figure 4 demonstrates the response in pa-
tient 1, whose blood sugar levels were almost uncontrol-
lable, with a fasting blood glucose of495 mg/dL, despite
administration of 90 U of insulin on the day before sur-
gery. By the 6th postoperative day, she no longer re-
quired insulin, and by the end of the first month, her
fasting blood glucose fell to 155 mg/dL. Within 3
months, her fasting blood glucose and glycosylated he-
moglobin levels returned to normal. Figure 5 compares
the changes in glucose and insulin levels in three groups:
morbidly obese patients with NIDDM, morbidly obese
non-NIDDM patients, and lean control subjects. The
rapid fall in glucose levels in the patients with NIDDM
contrasts sharply with the mild elevation ofboth ofthese
indices in the nondiabetic group after surgery, thus fast-
ing alone may not account for the euglycemia in the
NIDDM and IGT groups. The differences in insulin lev-
els among the three groups are also shown.
A review of the 27 failed operations in which the pa-
tients did not return to euglycemia revealed that 10 of
these failures were due to staple line breakdowns, that is,
technical failures prevented their correction. When the
17 nonresponders with intact operations, that is, without
staple line breakdowns or anastomotic dilatation, were
compared with those patients with full control of dia-
betic indices, the data showed that the patients who
failed to revert to full euglycemia were older (48.0 vs.
40.7 years; p < 0.01) and their diabetes was of longer
duration (4.6 vs. 1.6 years; p < 0.04) than those with suc-
cessful control ofglucose and insulin levels.
It is also of interest that the gastric bypass can overcor-
rect the hyperglycemia. We have documented 43 epi-
sodes of hypoglycemia in 35 patients, 6 of whom were
from the NIDDM cohort, 1 from those with insulin-de-
pendent diabetes mellitus, 8 from those who presented
with IGT, and 20 from those with normal oral glucose
tolerance curves. Postgastric bypass hypoglycemia can
240O
Figure 5. A comparison of blood glu-
cose values and insulin levels after sur-
gery in two cohorts, one with eugly-
cemia and the other with NIDDM. The
insulin and glucose levels rise slightly
during the postoperative period in the
euglycemic patients but fall sharply in
those with NIDDM.
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be troublesome, with blood glucose levels as low as 27
mg/dL. We have treated these without therapeutic inter-
vention, urging these patients to carry sugar, and most
were self-limited, with corrections occurring usually
within 1 year.
Before surgery, 353 of the 608 patients (58.1%) had
hypertension. After surgery, this rate has been reduced to
14%. In addition to these improvements, patients almost
always demonstrated improvement of cardiopulmonary
function, clearance of sleep apnea, cessation of snoring,
control of asthma, clearance of peptic reflux, fewer limi-
tations ofphysical activity from arthritis, and restoration
of fertility. Mental health evaluations revealed marked
overall improvement in mood and mental health indica-
tors during the first 2 years after surgery. These gains,
however, eroded by the 3rd year, with a return to their
previous mood status, perhaps because some oftheir per-
sonal dreams in terms ofmates or socioeconomic success
were unrealized.
Complications
Complications diminished with increasing experience
and rose with the severity of the comorbidities. For the
whole series, including some patients with daunting
risks, perioperative mortality was 9 of608 (1.5%), with 5
dying of sepsis, 3 of pulmonary embolism, and 1 of an
unknown cause (perhaps dysrhythmias) shortly after dis-
charge. Perioperative morbidity, that is, during the first
30 days, included the following complications: minor
wound infections, 8.7%; wound seromas, 5.8%; severe
wound infections, 3.0%; anastomotic stenosis, 3.0%;
splenic tears, 2.5%; and subphrenic abscesses, 2.5%. Hos-
pital readmissions were required for 8.2% ofthe patients,
and 2.8% of the patients needed reoperations during the
early postoperative period. The total mortality over the
14 years was 34 of 608, with 9 perioperative and 25 late
deaths. The latter were divided into two groups, 13 from
emotionally related causes and 12 due to "more natural"
causes. The emotionally related deaths involved three
suicides, three cases of cirrhosis due to a return to drink-
ing, one case of bulimia, one case of pernicious anemia
due to a refusal to take vitamin B12, one case ofalcoholic
hepatitis, and four, perhaps more questionable, cases of
auto accidents. (Even though we have begun a regular
support group, there have been three such deaths in the 3
years since its commencement.) The other late "natural"
deaths included four of cardiac causes, two of cancer,
and one each of atherosclerosis, pneumonia, acquired
immunodeficiency syndrome, peritonitis, pulmonary
embolus, and sepsis from a later operation.
The most frequent late complications were B12 defi-
ciency (40%), anemia (39%), hospital readmission
(38. 1%), incisional hernia (23.9%), depression (23.4%),
staple line failure (15. 1%), gastritis (13.2%), cholelithiasis
(1 1.4%), and bile reflux (8.7%). Dumping syndrome de-
veloped in 70.6% of the patients, but although this syn-
drome is sometimes listed as a complication, it is easily
controlled by the avoidance of sweets and is actually a
desired side effect.
DISCUSSION
The importance of our findings is not that gastric by-
pass can control diabetes in the morbidly obese, but that
NIDDM, previously considered a progressive and inexo-
rable disease, can be controlled for as long as 14 years.
What is the explanation for this remarkable control?
We can immediately rule out several of the traditional
approaches used in the treatment of NIDDM: exercise,
sulfonylureas, and insulin. None of these play a role in
the operative correction of diabetes. Morbidly obese pa-
tients do not exercise immediately after surgery, sulfo-
nylureas are never given after the operation, and insulin,
even when required initially for the 1st few postoperative
days, is rarely needed after the 1st week. The reason for
success must be associated with one of the changes in-
duced by surgery:
1. Limitation of total caloric intake.
2. Decrease of carbohydrates in the diet (sweets cause
dumping).
3. Exclusion of food from the hormonally active an-
trum, duodenum, and proximaljejunum by the by-
pass.
4. Delayed transit time from the stomach to the small
bowel because ofthe small gastric outlet.
5. Presentation of the midjejunum with undigested
food directly from the stomach.
There are several observations that offer clues in sort-
ing out the role ofeach ofthese changes:
1. The correction ofNIDDM occurs within days, long
before significant weight loss has occurred and long
before there is a significant reduction in the mass of
adipocytes.
2. The correction ofNIDDM is durable even though
most of these patients remain obese. (Although the
morbid obesity is almost always "cured," most pa-
tients do not return to an ideal body weight, but
remain, on the average, 50% above their ideal body
weight.)
3. The operation prevents the progression of IGT to
NIDDM in 97.8% of the patients and, instead, re-
turns them to euglycemia.
4. The correction of the NIDDM is less likely in pa-
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tients who are older (48.0 vs. 40.7 years; p < 0.01)
and who have had the disease longer (4.6 vs. 1.6
years; p < 0.04), probably due to a lower cell re-
serve.
5. In the three morbidly obese patients with NIDDM
who underwent the vertical banded gastroplasty, an
operation that also limits food intake but does not
bypass any section of the foregut, the diabetes was
also corrected.
6. In a unique patient who had a sham operation, the
NIDDM also resolved rapidly when the patient was
given the same postoperative diet as the patients
who were treated with the gastric bypass. (The pa-
tient, a 48-year-old morbidly obese man with
NIDDM, was scheduled for a gastric bypass but
during surgery was found to have a stomach full of
food. We did not, therefore, proceed with the pro-
cedure but closed his incision and then requested
that he stay on the identical postoperative regimen
as if he had undergone the bypass. His levels of
blood glucose fell rapidly, similar to the correction
seen in the gastric bypass patients, but rose again
to preoperative levels as soon as he was unable to
maintain the diet, 4 weeks after the procedure.)
Accordingly, based on these observations, it is reason-
able to conclude that the gastric bypass controls NIDDM
through the reduction of caloric intake. Whether the re-
alignment of intestinal flow with the exclusion ofthe an-
trum, duodenum, and proximal jejunum as well as the
presentation ofundigested food to the midjejunum plays
an additional role is not known, because we lack a defin-
itive comparison between the effects ofthe gastric bypass
and the gastroplasty. The observation by Sugerman's
group3 that gut hormone changes are more profound
with the bypass than with the vertical banded gas-
troplasty suggests that such a comparison may demon-
strate additional effects ofthe bypass on glucose metabo-
lism.
The relationship between obesity, that is, the increased
intake of food, and diabetes and the improvement of di-
abetes with weight control was noted even in the earliest
descriptions of the disease. Most patients older than age
50 with NIDDM are overweight.4 However, dietary con-
trol of NIDDM has generally been disappointing. Al-
though diets can improve glucose metabolism in the
obese, the improvement usually represents only a partial
and usually brief return to euglycemia, even when pa-
tients appear to comply. In the study of the effect of diet
on diabetes by Doar et al.,5 18 obese patients with newly
diagnosed NIDDM were subjected to a rigorous diet that
produced a significant weight loss of 5.1 ± 4.0 kg within
2 months. Even so, the average reduction in the fasting
plasma glucose was only from approximately 250 to 170
mg/dL, and random blood glucose levels were below 140
mg/dL in only 59% of the group. Although these values
reflect improvement, the reversal of NIDDM is not
nearly so complete as it is after the gastric bypass.
Our studies of insulin resistance at the cellular level
also support the theory that NIDDM is the result ofobe-
sity, that is, increased food intake. Because muscle is the
site of utilization of approximately 80% of the glucose
ingested in a meal, we studied the mechanism(s) causing
insulin resistance in rectus abdominis muscle oflean and
obese patients undergoing abdominal surgery. Very thin
muscle fiber strips were incubated in vitro to make met-
abolic measurements, including rates of glucose
transport, glycogen synthesis, and glycolysis.6 With this
preparation, we demonstrated that insulin stimulation of
glucose transport, which is the limiting step in glucose
utilization, is depressed in muscle7 ofmorbidly obese pa-
tients with or without diabetes. The degree of insulin re-
sistance is correlated with the degree of obesity up to a
body mass index of approximately 30,8 after which there
is little further change.
IfNIDDM can be controlled so completely by the re-
duction of caloric intake followed by a rapid decrease in
insulin levels and insulin resistance long before there is
any significant reduction in the mass of adipose tissue, it
is also reasonable to conclude that the lesion ofNIDDM
must be related to food intake and the signaling mecha-
nisms stimulated by that food. If that hypothesis is true,
it follows that the increased insulin resistance ofNIDDM
may not be the cause, but rather, an effect of the disease.
What are these signaling mechanisms? The gastrointesti-
nal tract, on contact with food and especially with carbo-
hydrates, stimulates insulin secretion through the release
of endocrine transmitters, also known as incretins. The
incretin effect denotes the phenomenon that glucose elic-
its a higher f-cell secretory response when administered
through the gut as compared with the intravenous route.
Increting hormones, then, are endocrine insulinotropic
factors released from the gut in response to glucose (or,
less strictly, nutrient) ingestion. Two gut peptides have
been identified as incretins: glucagon-like peptide- 1 (7 to
36) amide (glucagon-like insulinotropic peptide) and
glucose-dependent insulinotropic polypeptide (gastric
inhibitory peptide).9-12 (None ofthe other peptides from
the gut, that is, cholecystokinin, gastrin, or secretin, are
thought to be involved in the regulation of insulin in hu-
mans.) There may be other incretins that are unidenti-
fied. For further information, refer to Creutzfeldt and
Nauck. 12
The errors in signaling probably are not confined to
the gut. Further evidence ofa broader faulty glucose me-
tabolism signaling system is our finding that decreased
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tissue content of glucose transport protein'3 is not the
cause for this decrease in transport. 4 In addition, the glu-
cose transport effector system operates normally in insu-
lin-resistant muscle of obese individuals if an appropri-
ate signal is generated. 15,16 These results suggest that the
defect causing insulin resistance is in the insulin signal-
ing system of muscle. To confirm this conclusion, we
have shown that the tyrosine kinase activity of the insu-
lin receptor is decreased in morbidly obese individuals
with or without diabetes'7 and that this change in recep-
tor kinase activity is the most likely cause of the de-
creased phosphorylation of insulin receptor substrate- 1
and activation of phosphatidylinositol 3-kinase in obese
muscle. 8
Our clinical observations do not support the beliefthat
the islets are sick in the early stages ofNIDDM. In fact,
as shown in Figure 6, the islets in the morbidly obese
patients with NIDDM are initially normal and are able
to produce three times as much insulin as those of
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Figure 7. The importance of the size of the gastric outlet. A comparison
of weight loss achieved by patients with stomas of approximately 1 cm
compared with that seen in individuals with stretched anastomoses.
Figure 6. The progression of
NIDDM. In lean subjects, the glu-
cose level is maintained by low lev-
els of insulin secretion. With in-
creasing obesity, that is, increasing
food intake, the maintenance of
glucose at normal levels requires
increasing amounts of insulin.
Non-insulin-dependent diabetes
mellitus occurs when the islets are
no longer capable of secreting
enough insulin, more than three
times the normal output, to keep
glucose under control.
healthy control subjects before finally failing under the
continued stimulation, perhaps due to accumulation of
amylin faster than it can be cleared.
The lesion ofNIDDM, however, is not based on high
food intake alone. Genetics clearly plays an important,
but still undefined, role. One third ofour morbidly obese
patients have normal glucose metabolism, despite mas-
sive obesity. These patients appear to have a different dis-
tribution offat as well, with a greater tendency to be pear-
shaped than apple-shaped, that is, the patients without
diabetes have a gynecoid appearance, with the fat distrib-
uted to hips and breasts, rather than the android confor-
mation, with a large concentration of abdominal fat.
Most of our patients with NIDDM have strong family
histories of diabetes.
Differences in the characteristics and genetic expres-
sions of the adipocytes from the NIDDM and non-
NIDDM morbidly obese patients are being studied in
several centers, including ours. We have conducted stud-
ies that revealed differences in the physical, chemical,
and biologic properties ofplasma lipoproteins in insulin-
resistant patients compared with that of insulin-respon-
sive subjects. Plasma low-density lipoprotein (LDL)
molecules of insulin-resistant patients tended to be
smaller and more dense than LDL of control patients.
These changes in the physical properties of LDL could
be attributed to changes in the chemical composition of
LDL, which included a decrease in the cholesterol ester
content and an increase in the protein content of these
particles.'9 The changes in the physical and chemical
properties ofthe lipoproteins appear to affect the biologic
function ofLDL, as is evident from our studies. We have
shown that cells that depend on exogenous cholesterol
for growth and proliferation did not grow as fast when
cultured in the presence ofLDL of insulin-resistant pa-
tients, compared with cells grown in the presence ofLDL
Ann. Surg. . September 1995
Vol. 222 * No. 3
ofcontrol patients. We confirmed these findings with a
comparison of the properties ofLDL in morbidly obese
patients with NIDDM before and after gastric bypass
surgery.
Study Limitations
There are several limitations to our study and our hy-
pothesis. First, the claim that NIDDM is controlled by
the gastric bypass needs to be supported with evidence
that the complications of diabetes are also avoided. We
are encouraged by our finding in these patients that LDL
reverted to a more normal pattern with respect to physi-
cal, chemical, and biologic properties.2' There is also
some evidence in patients with NIDDM that the level of
glycemic control is a major predictor of the early devel-
opment of proliferative retinopathy and that hyperinsu-
linemia is a factor in the progression of coronary artery
disease.22 (Whether these conclusions can be extrapo-
lated to patients with NIDDM remain unclear.) Even so,
although it is true that none of our 608 patients have
suffered renal failure, progressed to blindness, or re-
quired an amputation, our group is too small in terms of
statistical power for us to claim that the gastric bypass
prevents diabetic system failures.
The second limitation is the lack of assays of glucose-
dependent insulinotropic polypeptide and glucagon-like
insulinotropic peptide to support the hypothesis (1) that
these incretin levels are high in the morbidly obese, (2)
that high incretin levels can cause exhaustion of the is-
lets, and (3) that these levels fall after bariatric proce-
dures. We have recently sent specimens, drawn from
NIDDM subjects before and after bariatric surgery, for
analysis to Gutniak in Vallingby, Sweden, but the results
are not yet available. Even that study is limited by the
fact that there may be other incretins, perhaps even more
powerful, that have not been identified.
The third limitation is the lack of a prospective, rigor-
ous comparison between the gastric bypass and one of
the gastric banding procedures in terms ofthe efficacy of
diabetic control. Kuzmak's23 adjustable gastric banding
procedure would be an excellent choice for such a study.
CONCLUSION
Non-insulin-dependent diabetes mellitus is no longer
an uncontrollable disease. A return to normal levels of
plasma glucose, insulin, and glycosylated hemoglobin
are now attainable with gastric bypass in the majority of
morbidly obese diabetic patients, especially if the ther-
apy can be initiated in the first 2 years after the diagnosis
of the disease. Whether the other bariatric procedures,
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such as the gastroplasties, produce similar levels of con-
trol remains to be determined.
Why the operation controls diabetes so well is not
clear, but the major reason appears to be the reduction
of caloric intake. There is some evidence that changes in
the incretin stimulation of the islets by the gut may also
play a role.
These studies provide new insights and opportunities
to understand NIDDM and predict, with control of obe-
sity, that this devastating disease may be curable.
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Discussion
DR. LLOYD D. MACLEAN (Montreal, Quebec): I agree that
surgery for obesity is gaining acceptance within the medical
profession. This is in no small measure, I think, due to the
efforts of Dr. Pories and his colleagues. It is also due to the will-
ingness ofthe American Surgical Association to hear of the in-
terests of its members, no matter how controversial. The first
paper on this was given by Arnold Kremen in 1954. Some of
you will remember that.
Dr. Pories has reported a large series with impressive results,
and an even more remarkable follow-up, which he did not em-
phasize during his presentation.
We perform a similar operation with a small pouch, 10 to 15
mL. It is isolated from the rest of the stomach and the fundic
side is inverted so there can be no mucosa-to-mucosa approxi-
mation. The operation is not dependent on staples. It is placed
in the dependent position along the lesser curve ofthe stomach
so there is no enlargement of the pouch over time. In contrast
to Dr. Pories, we have made the anastomosis initially with a
running nonabsorbable Prolene suture (Ethicon, Somerville,
NJ). But when we rescoped those people 1 or 2 years later, we
invariably found the Prolene in the lumen. The anastomosis
was the size of the jejunum and not confined by the running
suture.
We have gone on to perform this operation without any at-
tempt at narrowing the anastomosis using an absorbable su-
ture. On 160 patients who have been followed between 3 and 7
years, 95% have a satisfactory result; that is, they are within
50% of ideal weight.
This only held for morbid obesity, that is, a body mass index
between 40 and 50 and when a primary operation was per-
formed. If it was a redo or revision operation, or if the patient
was super obese with a body mass index over 50, our results
were only 63% satisfactory. I wonder if Dr. Pories could com-
ment on that.
Ann. Surg. * September 1995
I have four very briefquestions.
How many ofyour patients do return to within 50% ofideal?
You give your results as means with a wide variation around
the mean; it is a little difficult to tell how many patients got a
satisfactory result.
You have made a very good point that visceral obesity is as-
sociated with insulin resistance, hyperinsulinemia, and im-
paired glucose intolerance. In addition, I think you have data
that are not in the paper on the dyslipedemic state, which is
the strongest, after smoking, predisposing factor for coronary
artery disease. I would be very interested in the incidence of
coronary artery disease in your 600 patients. Is this less than
might be expected in this group? Do they have to lose more
weight than you have found so effective in the treatment oftype
2 diabetes? There is a genetic predisposition to severe obesity
and its distribution. I wonder, does a strong family history in-
fluence the likelihood ofa successful result?
Finally, fewer super obese patients in our experience return
to normal. I wonder if this has been your experience? And I
wonder why that is? Do they eat more despite the operation
than morbidly obese people?
The suggestion has been made by the recent cloning of an
obesity gene that the product of that is a satiety substance re-
leased from fat cells throughout the body. This works in an ex-
ceedingly efficient manner for most of us, who gain approxi-
mately 10 kg over 20 years ofadulthood, which is equivalent to
about one too many carrot sticks a day.
I suspect this is a central defect in these people and they could
have all the satiety hormone floating around that they would
need, but it will not help and you will still have to operate on
those people.
DR. HARVEY J. SUGERMAN (Richmond, Virginia): A recent
publication in last month's New England Journal ofMedicine
(Leibel R, Rosenbaum M, Hirsch J. Changes in energy expen-
diture resulting from altered body weight. N Engl J Med 1995;
332:621-628) stated in the opening line of the abstract that,
"No current treatment for obesity reliably sustains weight
loss."
In the accompanying editorial, there is no mention ofgastric
surgery for obesity, but the possibility ofbrain surgery is raised
(Bennett W. Beyond overeating. N Engl J Med 1995: 332:673-
674).
The 14-year follow-up of gastric bypass patients from the
Greenville, North Carolina group under the leadership of Dr.
Pories emphasizes the dramatic long-term success this opera-
tion can provide. In addition to diabetes, it effectively reverses
in most patients hypertension, sleep apnea, obesity hyperventi-
lation, pseudo-tumor cerebri, venous stasis ulcers, gastroesoph-
ageal reflux, etc.
There are several other published studies, including our own,
documenting the long-term efficacy of gastric bypass for this
"intractable" problem.
In a previous study of glucose tolerance tests before and 1
year after vertical-banded gastroplasty or gastric bypass in se-
verely obese patients who did not require medication for dia-
betes, we noted that the gastric bypass was associated with the
loss of65% of excess weight, and vertical-banded gastroplasty,
